Radiant trial nsclc

To put the current subset analysis in perspective, however, Dr. Hanna said. He said the jury is still out on overall survival, but observed that the Food and Drug Aadministration granted accelerated approval for imatinib Gleevec in KIT-mutant gastrointestinal stromal tumors based on DFS alone. In an interview, Dr. Skip to main content. View on the News The jury is still out. Correspondence to Fred R. Reprints and Permissions.

Nat Rev Clin Oncol 12, — Download citation. Published : 10 November Issue Date : December Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Current Treatment Options in Oncology Advanced search. Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Skip to main content Thank you for visiting nature.

Subjects Chemotherapy Drug therapy Non-small-cell lung cancer Receptor pharmacology. Access through your institution. Buy or subscribe. This is a preview of subscription content. Change institution.

Buy article Get time limited or full article access on ReadCube. References 1 Pignon, J. Eligibility Criteria. Patients with carcinoid tumors are not eligible. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. J Clin Oncol. Epub Aug National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Non-small Cell Lung Cancer. Drug: Erlotinib Drug: Placebo. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :.

Actual Study Completion Date :. Placebo Comparator: Placebo Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.

Drug: Placebo Placebo tablet. San Francisco, California, United States, South Pasadena, California, United States, Colorado Springs, Colorado, United States, Hematology Oncology Associates of the Treasure Coast. Philadelphia, Pennsylvania, United States, Greenville, South Carolina, United States, Spartanburg, South Carolina, United States,